Ximelagatran v warfarin in patients with atrial fibrillation at risk of ischaemic stroke at mean 17.4 months*

OutcomesEvent rates per yearDifference (95% CI)
XimelagatranWarfarin
*CI defined in glossary.
†Intention to treat analysis.
‡On treatment analysis.
§Not significant.
All stroke and systemic embolism†1.6%2.3%−0.7% (−0.1 to 1.4)§
Major or minor bleeding‡25.8%29.8%−4.0% (−6.9 to −1.1)
Major bleeding‡1.3%1.8%−0.5% (−1.2 to 0.2)§